In both the CPCG and TCGA cohorts, patients whose tumor genomes harbored more than one ZNRF3-associated feature were at significantly higher risk of adverse outcomes than those whose genomes harbored one or fewer (Fig. 4E, F). This evidence concerns the gene ZNRF3 and neoplasm.